Last reviewed · How we verify

NCT03073382

Risk Factors Associated With Spontaneous Preterm Delivery Status Post Open Fetal Myelomeningocele Repair

Completed Last updated 3 January 2024
What this trial tests

trial testing Chart review in Myelomeningocele in 56 participants. Completed in 26 May 2017.

Timeline
1 January 2017
Primary endpoint
26 May 2017
26 May 2017

Quick facts

Lead sponsorUniversity of Nebraska
StatusCompleted
Study typeOBSERVATIONAL
Enrollment56
Start date1 January 2017
Primary completion26 May 2017
Estimated completion26 May 2017

Drugs / interventions tested

Conditions studied

Sponsor

University of Nebraska

Who can join

Adults 18 to 45, female only, with Myelomeningocele. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Chart review

Trials testing the same drug.

Other recruiting trials for Myelomeningocele

Currently open trials in the same condition.

Other University of Nebraska trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03073382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing